Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Quick facts
Phase 3 pipeline
- ACE-536 · Hematology
ACE-536 is an activin receptor ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.
Phase 1 pipeline
- ACE-031 · Oncology
Activates the activin receptor type II-A (ActRIIA), leading to increased myostatin inhibition. - ACE-041
- Dalantercept plus sorafenib
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA portfolio CI brief
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA pipeline updates RSS
Frequently asked questions about Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
What is Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA's pipeline?
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA has 1 drugs in Phase 3, 0 in Phase 2, 3 in Phase 1. Late-stage candidates include ACE-536.
Related
- Sector hub: All tracked pharma companies